title: Treating chronic myeloid leukaemia: NICE guidance.
abstract: Chronic myeloid leukaemia (CML) affects approximately 560 people annually in the UK. Although median age at diagnosis is 60 years (National Institute for Health and Clinical Excellence (NICE), 2012), CML occurs in all age groups (National Comprehensive Cancer Network (NCCN), 2012). It is a clonal myeloproliferative disorder which is characterized by a reciprocal translocation between chromosomes 9 and 22, resulting in the formation of the Philadelphia chromosome (Ph Chromosome) and the development of an unregulated tyrosine kinase (BCR-ABL) which is responsible for the pathogenesis of CML (NCCN, 2012).
authors.affiliation: School of Nursing and Midwifery National University of Ireland, Galway, Ireland.
authors.forename: Maura
authors.initials: M
authors.lastname: Dowling
authors.forename: Teresa
authors.initials: T
authors.lastname: Meenaghan
authors.forename: Mary
authors.initials: M
authors.lastname: Kelly
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000451:nursing; D008495:Medical Oncology / Q000592:standards*; D009859:Oncology Nursing; D017410:Practice Guidelines as Topic / Q000592:standards*; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents